Medtronic plc, a global leader in healthcare technology, has announced a significant milestone in the regulatory review process for its INFUSE™ Bone Graft for Transforaminal Lumbar Interbody Fusion $(TLIF)$ procedure. Following a successful interim analysis, the independent Data Monitoring Committee recommended stopping further enrollment in the ongoing randomized controlled trial, citing early success. Medtronic is now preparing a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) to continue advancing this innovative spine surgery technology. Additionally, the company plans to apply for a New Technology Add-on Payment $(NTAP)$ with the U.S. Centers for Medicare & Medicaid Services, aiming to enhance the economic value of this innovation. This progress underscores Medtronic's commitment to bringing transformative technology to patients efficiently and responsibly.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。